IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
IOL Chemicals & Pharmaceuticals published its audited Q4 and full-year FY2026 results (ended 31 March 2026) in major newspapers on 21 May 2026. For standalone FY2026, total income was flat at ₹2,101.62 crore versus ₹2,101.61 crore in FY2025, while net profit after tax declined to ₹99.63 crore from ₹137.89 crore in the prior year. EPS for the year came in at ₹4.69 versus ₹3.44 in FY2025. Q4 standalone net profit (before tax) was ₹70.83 crore, up from ₹44.90 crore in Q4 FY2025. The results were reviewed by the Audit Committee and approved by the Board on 20 May 2026. Consolidated total income for FY2026 stood at ₹2,340.44 crore with net profit after tax of ₹101.00 crore.
While full-year standalone revenue was flat, net profit declined year-on-year, suggesting margin pressure. However, Q4 showed strong sequential recovery in profitability. Investors should monitor whether the profit recovery in Q4 signals a turnaround or is seasonal in nature.